Disseminated Amphotericin-Resistant Fusariosis in Acute Leukemia Patients: Report of Two Cases

Mycopathologia

Volumn 175, Issue 1-2, 2013, Pages 107-114

  Pereira, Graziella Hanna ^a   de Angelis, Derlene Attili ^b   Brasil, Roosecelis Araujo ^c   dos Anjos Martins, Marilena ^c   de Matos Castro e Silva, Dulcilena ^c   Szeszs, Maria Walderez ^c   de Souza Carvalho Melhem, Marcia ^c  

^a Brigadeiro Hospital   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Amphotericin resistant; Antifungal; Fusariosis; Fusarium solani; Leukemia

Indexed keywords

FUSARIUM; FUSARIUM SOLANI;

EID: 84872784493     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-012-9585-0     Document Type: Article

References (33)

1. Tezcan G, Ozhak-Baysan B, Alastruey-Izquierdo A, Ogunc D, Ongut G, Yi{dotless}ldi{dotless}ran ST, Hazar V, Cuenca-Estrella M, Rodriguez-Tudela JL. Disseminated fusariosis caused by Fusarium verticillioides in an acute lymphoblastic leukemia patient after allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2009; 47: 278-81.
2. Jossi M, Ambrosioni J, Macedo-Vinas M, Garbino J. Invasive fusariosis with prolonged fungemia in a patient with acute lymphoblastic leukemia: case report and review of the literature. Int J Infect Dis. 2010; 14: e354-6.
3. Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed. 2006; 77: 32-5.
4. Kontoyiannis DP, Bodey GP, Hanna H, Hachem R, Boktour M, Girgaway E, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma. 2004; 45: 139-41.
5. Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses. 1999; 42: 543-8.
6. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007; 20: 695-704.
7. Tortorano AM, Prigitano A, Dho G, Esposto MC, Gianni C, Grancini A, Ossi C, Viviani MA. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from Northern Italy. Antimicrob Agents Chemother. 2008; 52: 2683-5.
8. Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000; 111: 272-6.
9. Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 1994; 28: 7-15.
10. White TJ, Bruns T, Lee S, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. New York: Academic Press Inc.; 1990. p. 315-22.
11. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser UK. 1999; 41: 95-8.
12. Soll DR. The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev. 2000; 13: 332-70.
13. Kovacicova G, Spanik S, Kunova A, et al. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis. 2001; 33: 367-74.
14. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood. 1997; 90: 999-1008.
15. Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2004; 23(11): 1059-61.
16. Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994; 7(4): 479-504.
17. Gupta AK, Baran R, Summerbell RC. Fusarium infections of the skin. Curr Opin Infect Dis. 2000; 13: 121-8.
18. Azor M, Gene J, Cano J, Manikandan P, Venkatapathy N, Guarro JV. Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J Clin Microbiol. 2009; 47: 1463-8.
19. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother. 2002; 46: 3298-300.
20. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999; 37: 3946-51.
21. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodri{dotless}guez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. Antimicrob Chemother. 2008; 61: 805-9.
22. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109, 496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother. 1997; 41: 841-3.
23. Nalim FA, Samuels GJ, Wijesundera RL, Geiser DM. New species from the Fusarium solani species complex derived from perithecia and soil in the old World tropics. Mycologia. 2011; 103: 1302-30.
24. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol. 1998; 36: 198-202.
25. Teixeira AB, Moretti ML, Trabasso P, von Nowakonski A, Aoki FH, Vigorito AC, Miyaji M, Nishimura K, Taguchi H, Schreiber AZ. Evaluation of Fusarium solani hyphae and conidia susceptibility to amphotericin B and itraconazole: study of a clinical case. Mycopathologia. 2005; 160: 291-6.
26. Pujol I, Guarro J, Gené J, Sala J. In vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother. 1997; 39: 163-7.
27. Taylan Sekeroglu H, Erdem E, Yagmur M, Gumral R, Ersoz R, Ilkit M, Harbiyeli II. Successful medical management of recalcitrant Fusarium solani Keratitis: molecular identification and susceptibility patterns. Mycopathologia. 2012; 174: 233-727.
28. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41: 1364-8.
29. Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, Voltarelli JC, Colombo AL, Imhof A, Pasquini R, Maiolino A, Souza CA, Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004; 38: 1237-42.
30. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, van Lint MT, Falcucci P, Valentini CG, Girmenia C. Nosari AThe epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006; 91: 1068-75.
31. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010; 60: 331-7.
32. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad I, Sitbon K. French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010; 54: 4446-50.
33. Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine. 2011; 90: 69-80.